Previous studies suggested that the risk signature based on m6A RNA methylation regulators, METTL3 and METTL14, was of great value for prognosis prediction and closely associated with clinicopathological traits in ccRCC (Zhang et al., 2020). The gene discussed is METTL14; the disease is nonpapillary renal cell carcinoma.